Established in 1891, the Washington State Pharmacy Quality Assurance Commission (WA Pharmacy Commission) regulates the practice of pharmacy, and the distribution, manufacturing, and delivery of pharmaceuticals within and into the state. The commission protects and promotes public health and safety by issuing licenses, registrations, and certifications to qualified persons and entities and responding to complaints or reports of unprofessional conduct. The Commission is assigned the authority to enforce and change the schedule of controlled substances in Washington state.
Washington State Pharmacy Quality Assurance Commission
(WA Pharmacy Commission)
Public
Observations
The Week Ahead
(February 14, 2022)
By Tuesday evening, most bills would need to be voted out of their house of origin to continue, but three important—and contentious—cannabis-related bills remained unmoved.
The Week Ahead
(February 7, 2022)
After a brutal week for cannabis-related legislation which saw more than half rendered inactive, legislators prepared to undertake key debates on synthesized cannabinoids, community reinvestment, and social equity.
The Week Ahead
(January 31, 2022)
Policy committees rushed to recommend legislation ahead of the initial cutoff deadline on February 3rd, including bills on retail safety, cannabinoid regulation, and social equity.
The Week Ahead
(January 24, 2022)
24 cannabis-related bills were active and 11 were scheduled for committee activity in the week ahead, including social equity, craft endorsements, and WSLCB request legislation.
The Week Ahead
(January 17, 2022)
Washington State House and Senate policy committees had full schedules for the second week of the short session as 21 cannabis-related bills vied for legislator attention - including four newly introduced.
The Week Ahead
(August 30, 2021)
The Governor’s Council on Health Disparities planned to convene for the first time since December 2020 as policymaker attention began focusing on the 2022 legislative session.
WSLCB - Board Caucus
(April 27, 2021) - Delta-8-THC
The day before releasing a policy statement on delta-8-THC and other derived cannabinoids, board and staff discussed their work amidst often anecdotal input from stakeholders.
WA Pharmacy Commission - Public Meeting
(April 23, 2021) - Interpretation of THC Statute
At the request of WSLCB and with some hedging after hearing from stakeholders, the Pharmacy Commission affirmed a “plain language reading” of the controlled substances act definition of ‘THC’.
WSLCB - Board Caucus
(May 4, 2021) - Delta-8-THC
Policy and Rules Manager Kathy Hoffman walked the board through the past, present, and future of WSLCB regulation of cannabinoids aside from delta-9-THC in legal cannabis products.
WSLCB - Board Meeting
(April 28, 2021) - Summary
The Board proposed rules to double tier 1 producer canopy and heard comments calling for incentivized medical cannabis production and regulation of delta-8-THC.